Comparison

SARS-CoV-2 (COVID-19) Envelope Antibody

Item no. PRS-9169-0.02mg
Manufacturer ProSci
Amount 0.02 mg
Quantity options 0.02 mg 0.1 mg
Category
Type Antibody Primary
Format Liquid
Applications WB, IHC, ELISA
Specific against Virus
Host Rabbit
Isotype IgG
Conjugate/Tag Unconjugated
Citations Gorbalenya. bioRxiv: 2020.
Hui et al. Int J Infect Dis. 2020;91:264-266.
Pervushin et al. PLoS Pathog. 2009; 5(7): e1000511.
NCBI E
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Alias SARS-CoV-2 (COVID-19,2019-nCoV) Envelope Antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),Envelope protein,E protein
Shipping Condition Cool pack
Available
Manufacturer - Type
Primary Antibodies
Shipping Temperature
Blue Ice
Storage Conditions
SARS-CoV-2 (COVID-19) Envelope antibody can be stored at 4˚ C up to one year. Antibodies should not be exposed to prolonged high temperatures.
Manufacturer - Research Area
Infectious Disease, COVID-19
Background
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic corona virus E proteins, and also viral replication (3).
By Type
Infectious Disease, COVID-19
Badges
Trial Size, New
Protein Gi #
1791269092
Purification
SARS-CoV-2 (COVID-19) Envelope Antibody is affinity chromatography purified via peptide column.
Concentration
1 mg/mL
Buffer
SARS-CoV-2 (COVID-19) Envelope Antibody is supplied in PBS containing 0.02% sodium azide.
Application Note
IHC: 0.5 μ g/mL; WB: 1-2 μ g/mL;
Antibody validated: Immunohistochemistry in human samples. SARS-CoV-2 (COVID-19) Envelope antibody can detect 2 ng of free peptide at 1 μ g/mL in ELISA. It can detect SARS-CoV-2 Envelope recombinant protein by ELISA and WB. All other applications and species not yet tested.
Homology
Predicted reactivity based on immunogen sequence: SARS-CoV Envelope proteins: (93%)
Immunogen
Anti-SARS-CoV-2 (COVID-19) Envelope antibody (9169) was raised against a peptide corresponding to 14 amino acids near the carboxyl terminus of SARS-CoV-2 (COVID-19) Envelope protein.

The immunogen is located within the last 50 amino acids of SARS-CoV-2 (COVID-19) Envelope protein.
Clonality
Polyclonal
NCBI Official Name
envelope protein
NCBI Organism
Wuhan seafood market pneumonia virus
Disclaimer
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
User Note
Optimal dilutions for each application to be determined by the researcher.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 0.02 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close